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Abstract
Since 2012, U.S. clinical guidelines for antiretroviral therapy (ART) initiation have recommended 
universal ART prescription barring patient contraindications. Although ART prescription has 
significantly increased among U.S. HIV patients in recent years, the reasons for this increase, and 
why some patients are still not taking ART, are not well characterized. We lack information on the 
proportion of patients deferring ART based on the advice of their provider, whether these patients 
differ from patients deferring ART for other reasons, and whether provider-advised ART deferral 
has decreased as guidelines have moved towards universal ART prescription. Further, few have 
examined reasons for ART deferral among patients in diverse care settings, which can inform 
efforts to increase, and identify reasons for inequities in ART use.
To fill these gaps, we analyzed data from the Medical Monitoring Project (MMP), which conducts 
interviews and medical record abstraction on annual probability samples of U.S. HIV patients. We 
assessed the proportion of persons who reported provider-advised ART deferral during 2009-2014, 
and used bivariate linear regression to estimate linear trends in provider-advised ART deferral over 
time by patient characteristics and clinical setting.
During this period, the proportion of patients reporting provider-advised ART deferral decreased 
from 67% to 40%. Significant decreases were observed in all patient subgroups and clinical 
settings. Patients recently reporting non-provider-advised reasons for ART deferral were 
significantly less likely to be virally suppressed and more likely to have inconsistent care, be 
depressed, binge drink, and use illicit drugs.
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This work suggests that U.S. providers are recommending ART deferral for fewer patients, 
consistent with increasing adoption of 2012 universal prescribing guidelines. Addressing patients’ 
financial, mental health, and substance use barriers may be needed to achieve universal ART 
prescription in the United States.
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Introduction
Antiretroviral therapy (ART) use and subsequent viral suppression decrease HIV-related 
morbidity and HIV transmission (Cohen et al., 2016; May et al., 2014). Since 2012, U.S. 
guidelines for ART initiation have recommended universal ART prescription barring patient 
contraindications (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2016). 
Although there were significant increases in ART prescription from 2009–2013 among 
adults receiving HIV care (Bradley et al., 2016), the reasons for these increases have not 
been thoroughly examined. One likely explanation is declining provider-advised ART 
deferral as providers adopt clinical guidelines, and population-based estimates for 2013–
2014 indicated that nearly three-quarters of HIV care providers reported initiating ART for 
all patients, barring contraindications (Weiser et al., 2017). However, we lack information on 
the proportion of patients deferring ART based on the advice of their provider, whether these 
patients differ from patients deferring ART for other reasons, or whether provider-advised 
ART deferral has decreased as guidelines have moved towards universal ART prescription. 
Further, few have examined reasons for ART deferral among patients in diverse care 
settings, which could help inform efforts to increase, and identify reasons for inequities in, 
ART use.
We assessed trends from 2009 to 2014 in self-reported reasons for ART deferral among HIV-
positive adults in care, overall and by patient characteristics and clinical setting. To 
characterize recent ART deferral, we estimated prevalence of, and factors associated with, 
provider-advised versus other reasons for ART deferral for patients receiving HIV care 
during 2013–2014.
Materials and Methods
The Medical Monitoring Project (MMP) is a national HIV surveillance system that produces 
annual, cross-sectional estimates of behavioral and clinical characteristics of HIV-positive 
adults (Bradley et al., 2014). MMP data collection is part of routine public health 
surveillance and was determined to be nonresearch. Informed consent was obtained from all 
interviewed participants. For the 2009–2014 data collection cycles, MMP used a 3-stage 
design to sample HIV-positive adults receiving outpatient medical care (i.e., states, 
outpatient HIV care facilities, and patients). Data were collected via face-to-face or 
telephone interviews and medical records were abstracted at the sampled facility. Response 
rates were 100% at the state/territory level, facility response ranged between 76–86%, and 
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patient response ranged between 49–56%. Data were weighted on the basis of known 
probabilities of selection and were adjusted for facility and patient non-response.
Using annual cross-sectional MMP data representing U.S. HIV patients during 2009–2014 
(n=28,124), we estimated the overall percentage deferring ART by year. Among 1,908 
persons who reported deferring ART at the time of interview, we examined patients’ self-
reported primary reason for deferring ART in 2009 and 2014. Reasons for deferral included 
provider-advised ART deferral, feeling healthy, side effects, money or insurance problems, 
or other reasons (e.g. depression, being worried about adherence, denial, drinking or using 
drugs). We assessed the proportion of persons who reported provider-advised ART deferral 
(versus all other reasons for deferral) during 2009–2014, and used bivariate linear regression 
to estimate linear trends over time by history of ART use (ART naïve vs. ART experienced), 
geometric mean CD4 t-lymphocyte cell (CD4) count over the past 12 months (<500 vs. 
≥500), care at facility receiving Ryan White HIV/AIDS program (RWHAP) funding, facility 
ownership type (public vs. private), and facility HIV patient load (≤400 vs. >400 patients). 
In the linear models, βTREND represents the average annual percentage point change over the 
years examined. In the graphs, 2012 is highlighted to show the year in which U.S. guidelines 
began recommending universal ART prescription barring patient contraindications.
To characterize ART deferral in the most recent time period for which we had data, 2013–
2014, we assessed differences between patients deferring ART based on the advice of their 
provider compared with patients giving other reasons for ART deferral using Rao-Scott chi-
square tests. We assessed differences overall and by age, gender, non-Hispanic black or 
African American race/ethnicity (hereafter referred to as black), gay or bisexual identity, 
educational attainment, household at or below the poverty level, type of health coverage or 
insurance (any private insurance, public insurance only, uninsured/only RWHAP program 
funding), homelessness and incarceration in the past 12 months, length of time since HIV 
diagnosis, regular care utilization (≥1 viral load in each 6 month period), symptoms of major 
or other depression in the past 2 weeks based on the Patient Health Questionnaire 8, binge 
drinking (≥5 alcoholic beverages for men and ≥4 for women in a single sitting), any illicit 
drug use, and viral suppression (most recent viral load undetectable or ≤ 200 copies/mL). 
Statistical significance for all tests was defined as p<0.05. All analyses accounted for the 
complex sample design and weights.
Results
From 2009 through 2014, the proportion of U.S. HIV patients deferring ART decreased 
from 12% (95% confidence interval [CI:11–13]) to 4% (CI:3–4) (P TREND<0.0001, 
βTREND=−0·02). In 2009, reported reasons for deferring ART were provider advised (67%, 
CI:61–72), feels healthy (9%, CI:6–13), side effects (7%, CI:5–10) and other reasons 
including depression, being worried about adherence, denial, drinking or using drugs (13%, 
CI:10–16). The proportion reporting money or insurance as a reason for ART deferral in 
2009 was 3% (CI:1–5) but this estimate was unstable due to small sample size. By 2014, 
reported reasons for deferring ART were provider advised (40%, CI:34–47), feels healthy 
(14%, CI:8–19), side effects (7%, CI:4–10) and other reasons (25%, CI:20–30). The 
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proportion reporting money or insurance as a reason for deferring ART in 2014 was 14% 
(CI:8–19).
From 2009 through 2014, there was a significant overall decrease in participants reporting 
provider-advised ART deferral, from 67% to 40% (Figure 1). Although ART deferral was 
less common among ART-experienced patients compared to ART-naïve patients, both 
groups had significant decreases in provider-advised ART deferral, as did those with 
geometric mean CD4 counts <500 and ≥500. Provider-advised ART deferral significantly 
decreased among patients attending both RWHAP-funded and non-funded facilities, 
although the former had larger annual estimated decreases (βTREND= −0·06 for RWHAP-
funded versus −0·02 for non-funded facilities, Figure 2). Significant decreases were also 
seen among patients attending public and private facilities and those attending clinics with 
HIV patient loads of ≤400 and >400 patients.
In 2013–2014, provider-advised ART deferral was significantly more common among 
persons aged ≥50 years compared with those <50 years (51%, CI:42–59 vs. 39%, CI:33–45), 
blacks compared with non-blacks (51%, CI:42–59 vs. 32%, CI:23–41), those with regular 
versus not regular care utilization (51%, CI:42–61 vs. 33%, CI:26–40), those without vs. 
those with symptoms of depression (45%, CI:40–51 vs. 35%, CI:26–44), and those who did 
not use drugs compared with those who did (48%, CI:41–55 vs. 32%, CI:25–40). Viral 
suppression was significantly more common among those with provider-advised ART 
deferral versus those who deferred for other reasons (39%, CI:33–45 vs. 28%, CI:19–36).
Discussion
From 2009 through 2014, the percentage of patients reporting provider-advised ART 
deferral decreased an average of 5 percentage points per year. We documented significant 
decreases in provider-advised deferral among all examined patient sub-groups and HIV care 
facility characteristics. Based on patient reports, providers were increasingly less likely to 
defer ART for ART-experienced patients and those with lower CD4 counts. This is 
consistent with increasing adoption by providers of U.S. clinical guidelines, which 
recommended ART initiation barring any contraindications for patients with CD4 counts of 
<350 before 2009, at <500 in 2009 and universal initiation in 2012. The smallest decrease in 
provider-advised ART deferral was among patients attending HIV care facilities not funded 
by the RWHAP. As more providers adopt universal ART prescription, newer regimens with 
a higher barrier to resistance are developed, and long-acting ART regimens receive approval, 
we may see further decreases in provider-advised ART deferral.
The United States has moved from an era where the majority of HIV patients deferring ART 
were doing so based on the advice of their provider to one where reasons for ART deferral 
are more complex. The percentage of persons deferring ART who reported money or 
insurance problems as reasons for ART deferral increased. Although there were 
improvements in coverage for HIV care over the time period examined (Kates & Dawson, 
2017), poverty is extremely high among HIV patients (Centers for Disease Control and 
Prevention, 2016), and even those with coverage may face difficulties in affording 
medication copays. Further, lower educational attainment is common among HIV patients 
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(Centers for Disease Control and Prevention, 2016), which may result in difficulties in 
understanding or navigating the insurance or coverage systems that provide ART for some 
patients. Case management may help patients navigate financial and insurance barriers to 
ART use (Brennan-Ing et al., 2016).
Among persons deferring ART, the proportion citing other reasons for ART deferral such as 
depression, being worried about medication adherence, and drinking or drug use increased 
from 2009 to 2014. Compared to persons deferring ART based on the advice of their 
provider, we found that persons reporting other reasons for ART deferral were less likely to 
be virally suppressed and more likely to have inconsistent care, be depressed, and to binge 
drink and use illicit drugs. Although mental health and substance use problems are 
commonly cited by providers as a reason they would defer ART prescription (Weiser et al., 
2017), we found that persons with potential mental health and substance use problems were 
more likely to cite other reasons for ART deferral. This tendency may result from these 
problems being barriers to engagement in care (Mugavero, 2008), thus limiting opportunities 
for providers to interact with patients and make recommendations about ART. In addition to 
efforts to improve engagement in HIV care, increasing access to mental health and substance 
abuse counseling and treatment and adherence support services for those who need them 
may help. Our results suggest that providing support to help patients overcome these 
psychosocial barriers to ART use will be critical to achieve universal ART for clinically-
eligible persons receiving HIV care.
We also found that over half of black HIV patients reported provider-advised ART deferral 
compared with less than one-third of non-black patients. While more investigation is 
warranted, this may be due to racial/ethnic differences in patient-provider communication. 
Studies have found more provider verbal dominance and less patient provision of 
information in medical encounters with black compared to white HIV patients (Beach et al., 
2011; Laws et al., 2014).
A key issue beyond the focus of this analysis is that most HIV-positive persons deferring 
ART are not receiving medical care, so efforts to increase linkage to and engagement in care 
will be essential to realize the full treatment and prevention benefits of ART use for persons 
living with HIV and their partners. A limitation of our analysis is that reasons for ART 
deferral were reported by the patient and may differ from the provider’s perception 
(Christopoulos et al., 2015). However, efforts to increase ART use among clinically eligible 
persons must incorporate the patient’s perspective about their behavior in order to be most 
effective. Another limitation is that the patient interview and our measure of viral 
suppression were not necessarily contemporaneous, so some misclassification may exist.
In conclusion, HIV patient reports suggest that U.S. providers are recommending ART 
deferral for fewer patients, perhaps reflecting increasing adoption of 2012 universal 
prescribing guidelines. However, more work may be needed to address patients’ barriers to 
ART use apart from provider-advised deferral, particularly those related to financial barriers, 
mental health, and substance use.
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Figure 1. Trends in provider-advised Antiretroviral therapy (ART) deferral, overall and by 
selected patient characteristics—Medical Monitoring Project, United States, 2009-2014
Note: Dashed line denotes the year 2012, when U.S. guidelines began recommending 
universal ART prescription barring patient contraindications
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Figure 2. Trends in provider-advised antiretroviral therapy (ART) deferral by selected HIV care 
facility characteristics—Medical Monitoring Project, United States, 2009-2014
Note: Dashed line denotes the year 2012, when U.S. guidelines began recommending 
universal ART prescription barring patient contraindications
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